A GAB Aergic anxiolytic-like trait of thymoquinone, possibly via diazepam-co-agonistic pathway

  • Authors

    • Muhammad Islam LecturerDepartment of PharmacySouthern University BangladeshMehedibag-4000, Chittagong
    2017-07-16
    https://doi.org/10.14419/ijm.v5i2.7923
  • Anxiety, GABA, Thymoquinone, Swing Apparatus.
  • Abstract

    This study evaluated the possible anxiolytic potential of thymoquinone (TQ), a promising component of Nigella sativa oil in male Swiss mice under unstressed and stressed conditions. A short-term physical stress (STPS) was produced by using an electric shaker. A new apparatus named as ‘swing apparatus’ was selected to carry out this study. TQ was tested at doses of 5, 10 and 20 mg/kg. In order to understand possible action mechanism, a GABA receptor agonist and an antagonist were used in this study. As agonist diazepam (DZP), while antagonist flumazenil (FZL) was used at 2 and 2.5 mg/kg doses. Treatments were given intraperitoneally. The brain GABA levels were determined by UV-spectrophotometric method. The results suggest that, TQ dose-dependently exerted a significant (p<0.05) anxiolytic effect in rodents, which was confirmed by the calming effect of the experimental animals in comparison to the vehicles' NC, DZP and FZL groups. An augmentation of the movements of the animals was observed in STPS applied groups. GABA levels in the mouse brain were also found to link with the behavioral activity, where TQ co-treated with DZP augmented the calming effect by decreasing GABA levels, which was reversed by the FZL pre- and post-treated groups, demonstrating possible co-agonistic and antagonistic effects with DZP and FZL, respectively. Therefore, this study suggests an involvement of GABAergic, possibly DZP-co-agonistic anxiolytic-like effect of TQ.

  • References

    1. [1] Dell’osso B, Lader M. 2013. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A Critic. Reappraisal Eur. Psychiatr. 28:7-20. https://doi.org/10.1016/j.eurpsy.2011.11.003.
      [2] Gilhotra N, Dhingra D. 2011. Thymoquinone produced anti-anxiety-like effects in mice through modulation of GABA and NO levels. Pharmacol. Rep. 63:660-669. PMID: 21857076. https://doi.org/10.1016/S1734-1140(11)70577-1.
      [3] Griebel G, Holmes A. 2013. 50 years of hurdles and hope in anxiolytic drug discovery. Nat. Rev. Drug Discov. 12:667-687. https://doi.org/10.1038/nrd4075.
      [4] Islam MT, da Mata AMOF, de Aguiar RPS, Paz MFCJ, de Alencar MVOB, Melo-Cavalcante AAC. 2016b. Therapeutic Potential of Essential Oils Focusing on Diterpenes. Phytother. Res. 30:1420-1444. https://doi.org/10.1002/ptr.5652.
      [5] Islam MT, da Silva CB, de Alencar MVOB, Paz MFCJ, Al-meida FRC, Melo-Cavalcante AAC. 2016a. Diterpenes: Ad-vances in Neurobiological Drug Research. Phytother. Res. 30:915-928. https://doi.org/10.1002/ptr.5609.
      [6] Islam MT, Sultana N, Riaz TA, Ferdous J, Guha B, Mohagon S, Mutsuddy R, et al. 2016c. Thymoquinone is knocking at the door of clinical trial. Int. Arch. Med. 9(122):1-25. https://doi.org/10.3823/1993.
      [7] Islam MT, Freitas RM, Oliveira GLS, Guha B. 2014. Neuro-pharmacological screenings of hydroalcoholic fractions of Urena lobata L. World J. Pharm. Pharmaceut. Sci. 3:62-71.
      [8] Lowe IP, Robins E, Eyerman GS. 1958. The flourimetric measurement of glutamic decarboxylase and its distribution in brain. J. Neurochem. 3:8-16. PMID: 13611554. https://doi.org/10.1111/j.1471-4159.1958.tb12604.x.
      [9] Lu Y, Zhang H, Meng X, Wang L, Guo X. 2010. A validated HPLC method for the determination of GABA by pre-column derivatization with 2, 4-dinitroflurodinitrobenzene and its ap-plication to plant GAD activity study. Analytical Lett. 43:2663-2671. https://doi.org/10.1080/00032711003763558.
      [10] Rye DB, Bliwise DL, Parker K, Trotti LM, Saini P, Fairley J, et al. 2012. Modulation of Vigilance in the Primary Hyper-somnias by Endogenous Enhancement of GABAA Receptors. Sci. Transl. Med. 4:151-161. https://doi.org/10.1126/scitranslmed.3004685.
      [11] Tan KR, Rudolph U, Lüscher C. 2014. Hooked on benzodiaz-epines: GABAA receptor subtypes and addiction. Trends Neu-rosci. 34(4):188-197. https://doi.org/10.1016/j.tins.2011.01.004.

  • Downloads

  • How to Cite

    Islam, M. (2017). A GAB Aergic anxiolytic-like trait of thymoquinone, possibly via diazepam-co-agonistic pathway. International Journal of Medicine, 5(2), 186-189. https://doi.org/10.14419/ijm.v5i2.7923

    Received date: 2017-06-04

    Accepted date: 2017-07-07

    Published date: 2017-07-16